SELLAS Life Sciences Group (SLS) Competitors $1.16 -0.02 (-1.69%) Closing price 04:00 PM EasternExtended Trading$1.16 0.00 (0.00%) As of 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends SLS vs. PROK, TRML, TKNO, ESPR, RGNX, PRME, BNTC, TERN, ATYR, and IMMPShould you be buying SELLAS Life Sciences Group stock or one of its competitors? The main competitors of SELLAS Life Sciences Group include ProKidney (PROK), Tourmaline Bio (TRML), Alpha Teknova (TKNO), Esperion Therapeutics (ESPR), REGENXBIO (RGNX), Prime Medicine (PRME), Benitec Biopharma (BNTC), Terns Pharmaceuticals (TERN), Atyr PHARMA (ATYR), and Immutep (IMMP). These companies are all part of the "pharmaceutical products" industry. SELLAS Life Sciences Group vs. ProKidney Tourmaline Bio Alpha Teknova Esperion Therapeutics REGENXBIO Prime Medicine Benitec Biopharma Terns Pharmaceuticals Atyr PHARMA Immutep ProKidney (NASDAQ:PROK) and SELLAS Life Sciences Group (NASDAQ:SLS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, community ranking and media sentiment. Does the MarketBeat Community prefer PROK or SLS? SELLAS Life Sciences Group received 2 more outperform votes than ProKidney when rated by MarketBeat users. However, 57.14% of users gave ProKidney an outperform vote while only 55.56% of users gave SELLAS Life Sciences Group an outperform vote. CompanyUnderperformOutperformProKidneyOutperform Votes857.14% Underperform Votes642.86% SELLAS Life Sciences GroupOutperform Votes1055.56% Underperform Votes844.44% Do analysts rate PROK or SLS? ProKidney currently has a consensus target price of $5.00, indicating a potential upside of 424.82%. Given ProKidney's stronger consensus rating and higher probable upside, research analysts clearly believe ProKidney is more favorable than SELLAS Life Sciences Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProKidney 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50SELLAS Life Sciences Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is PROK or SLS more profitable? ProKidney's return on equity of 0.00% beat SELLAS Life Sciences Group's return on equity.Company Net Margins Return on Equity Return on Assets ProKidneyN/A N/A -10.24% SELLAS Life Sciences Group N/A -629.46%-178.65% Which has preferable valuation & earnings, PROK or SLS? ProKidney has higher earnings, but lower revenue than SELLAS Life Sciences Group. ProKidney is trading at a lower price-to-earnings ratio than SELLAS Life Sciences Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProKidneyN/AN/A-$35.47M-$0.55-1.73SELLAS Life Sciences Group$1M81.64-$37.34M-$0.69-1.68 Does the media favor PROK or SLS? In the previous week, SELLAS Life Sciences Group had 1 more articles in the media than ProKidney. MarketBeat recorded 3 mentions for SELLAS Life Sciences Group and 2 mentions for ProKidney. SELLAS Life Sciences Group's average media sentiment score of 1.58 beat ProKidney's score of 0.94 indicating that SELLAS Life Sciences Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProKidney 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SELLAS Life Sciences Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more risk & volatility, PROK or SLS? ProKidney has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. Comparatively, SELLAS Life Sciences Group has a beta of 2.43, meaning that its stock price is 143% more volatile than the S&P 500. Do institutionals and insiders hold more shares of PROK or SLS? 51.6% of ProKidney shares are owned by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. 41.5% of ProKidney shares are owned by company insiders. Comparatively, 1.2% of SELLAS Life Sciences Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryProKidney beats SELLAS Life Sciences Group on 10 of the 16 factors compared between the two stocks. Remove Ads Get SELLAS Life Sciences Group News Delivered to You Automatically Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLS vs. The Competition Export to ExcelMetricSELLAS Life Sciences GroupPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$81.64M$6.94B$5.63B$7.93BDividend YieldN/A2.72%4.89%4.05%P/E Ratio-1.686.1223.6518.74Price / Sales81.64219.88371.05119.09Price / CashN/A65.6738.0534.64Price / Book-4.646.616.854.19Net Income-$37.34M$139.99M$3.19B$247.07M7 Day Performance-2.52%-2.32%5.35%-2.82%1 Month Performance-8.66%-8.89%-1.03%-10.75%1 Year Performance-22.15%-4.99%12.50%0.56% SELLAS Life Sciences Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLSSELLAS Life Sciences Group0.8989 of 5 stars$1.16-1.7%N/A-14.5%$81.64M$1M-1.6810Positive NewsPROKProKidney1.8802 of 5 stars$1.10-11.0%$4.50+311.0%-34.0%$319.37MN/A-1.993Upcoming EarningsNews CoverageHigh Trading VolumeTRMLTourmaline Bio1.5679 of 5 stars$12.33-5.8%$54.67+343.4%-64.4%$316.18MN/A-4.3744Earnings ReportUpcoming EarningsAnalyst RevisionNews CoverageTKNOAlpha Teknova1.7881 of 5 stars$5.86-9.8%$8.50+45.1%+93.0%$312.39M$36.35M-7.92240Short Interest ↑ESPREsperion Therapeutics4.0604 of 5 stars$1.58-7.1%$6.75+327.2%-25.9%$311.32M$295.45M-2.47200RGNXREGENXBIO3.9751 of 5 stars$5.92-9.9%$34.70+486.1%-69.7%$293.31M$84.33M-1.18370PRMEPrime Medicine3.0761 of 5 stars$2.23-11.5%$13.13+488.6%-75.2%$292.49M$2.98M-1.09234Earnings ReportAnalyst RevisionBNTCBenitec Biopharma2.4726 of 5 stars$12.42-2.3%$24.43+96.7%+190.7%$291.26M$80,000.00-8.2320Short Interest ↑Gap UpTERNTerns Pharmaceuticals4.0765 of 5 stars$3.39-8.1%$18.30+439.8%-48.7%$287.94MN/A-2.8740ATYRAtyr PHARMA2.4417 of 5 stars$3.30-16.7%$18.60+463.6%N/A$277.01M$235,000.00-3.5153Short Interest ↑News CoverageIMMPImmutep1.8336 of 5 stars$1.86-3.6%$8.50+357.0%-33.3%$270.74M$5.14M0.002,021Positive NewsHigh Trading Volume Remove Ads Related Companies and Tools Related Companies ProKidney Alternatives Tourmaline Bio Alternatives Alpha Teknova Alternatives Esperion Therapeutics Alternatives REGENXBIO Alternatives Prime Medicine Alternatives Benitec Biopharma Alternatives Terns Pharmaceuticals Alternatives Atyr PHARMA Alternatives Immutep Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLS) was last updated on 3/13/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SELLAS Life Sciences Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SELLAS Life Sciences Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
